Ask HopeStage to review this study with me
Study ID: NCT05254405. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT05254405
An Open Label Study of IV Brexanolone for PTSD
This study has public registry information. It focuses on PTSD and currently lists study information in the United States.
PTSDDrugFrom 18 Years to 50 Years
Key information made simple
What is this study testing?
This study is testing whether IV Brexanolone may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive IV Brexanolone, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Terminated
- Estimated enrollment
- 10
- Sponsor
- Donald Jeffrey Newport
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- PHASE4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT05254405
- Official title
- An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05254405. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: Open-label study of brexanolone infusion for the treatment of posttraumatic stress disorder in 20 adult women with PTSD. Primary Objective: To determine if brexanolone injection infused intravenously for 24 hours at up to 60 μg/kg/h reduces PTSD symptom severity in a group of. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving Brexanolone Injection [Zulresso]. The listed phase is PHASE4. Ask the study team what that means in practice for safety, monitoring, and criteria.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 50 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Donald Jeffrey Newport, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status. The registry lists an estimated enrollment of 10 participants.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT03110575
12-Week Extension Study of TNX-102 SL in PTSD Patients
This study was terminated in the United States. It is testing TNX-102 SL for PTSD.
TerminatedNCT05260541
A study of PRAX-114 in people with PTSD
This study was terminated in the United States. It focuses on PTSD.
TerminatedNCT03841773
TNX-102 SL for PTSD
This study was terminated in the United States. It is testing TNX-102 SL for PTSD.